Personalized Medicine in Lung Cancer

Lung cancer is the leading cause of cancer death worldwide. In 2017 lung cancer mortality was 1.6 million people.Non-small cell lung cancer is the most common subtype histology among bronchogenic carcinoma and has a poor outcome. Five-year overall survival is about 20%. The majority of NSCLC patients present with advance stages. Platinum based combination chemotherapy has been the standard treatment in advanced disease for decades. But it prolongs the overall survival only by months. Until very recently this treatment has been without patient’s selection for histology and biomarkers. In recent years personalized medicine implies the use of standardized biomarkers to identify the driver mutations such as EGFR mutation, ALK and ROS1 rearrangement, BRAF mutation, RET fusion, MET amplification and others for selecting specific treatment to improve overall survival. Evaluation of individual tumor profiling for defining specific biomarkers in different histologic subtypes and also biomarkers for immunotherapies have had significant impact on overall survival in NSCLC patients. These targeted therapies and immunotherapies have revolutionized treatment strategies in lung cancer in the past few years.

کلیدواژه ها:

personalized medicine ، lung cancer ، driver mutation ، immunotherapy